Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2530 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Ticagrelor				
Initial application — acute coronary syndrome Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
	t 60 days) been diagnosed with an ST-elevation or a	non-ST-elevation acute coronary syndrome		
and Fibrinolytic therapy has not been g	iven in the last 24 hours and is not planned			
Renewal — subsequent acute coronary syndro Current approval Number (if known):				
Applications from any relevant practitioner. Approx				
Prerequisites(tick boxes where appropriate)				
	t 60 days) been diagnosed with an ST-elevation or a	non-ST-elevation acute coronary syndrome		
and Fibrinolytic therapy has not been g	given in the last 24 hours and is not planned			
Initial application — thrombosis prevention net Applications from any relevant practitioner. Approx Prerequisites(tick boxes where appropriate)				
Dations had a narratheric	and about time are an area of time the class CO days.			
or	cal stenting procedure* in the last 60 days			
	eurological stenting procedure performed*			
Patient has demonstrated cl assay and requires antiplate	opidogrel resistance using the P2Y12 (VerifyNow) as let treatment with ticagrelor	ssay or another appropriate platelet function		
	e has been demonstrated by the occurrence of a new	cerebral ischemic event		
, , , <u>—</u> , ,	e has been demonstrated by the occurrence of transic	ent ischemic attack symptoms referable to the		
stent				
Pengual thrombosic provention pourelogies	al atonting			
Renewal — thrombosis prevention neurological stenting Current approval Number (if known):				
Applications from any relevant practitioner. Approvals valid for 12 months.				
Prerequisites(tick boxes where appropriate)				
Patient is continuing to benefit from treatment				
Treatment continues to be clinically appropriate				

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2530 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number: Ticagrelor - continued		Fax Number:	
Initial application — Percutaneous coronary in Applications from any relevant practitioner. Approx Prerequisites(tick boxes where appropriate) Patient has undergone percutaneous and Patient has had a stent deployed in and Patient is clopidogrel-allergic**	ous coronary intervention		
Renewal — Percutaneous coronary intervention Current approval Number (if known):	vals valid for 6 months. ous coronary intervention		
Initial application — Stent thrombosis Applications from any relevant practitioner. Approvals valid without further renewal unless notified. Prerequisites(tick box where appropriate) Patient has experienced cardiac stent thrombosis whilst on clopidogrel			
Initial application — acute minor stroke or high Applications from any relevant practitioner. Approx Prerequisites(tick boxes where appropriate)			
and	a minor stroke (NIHSS† score 3 or less), high-risk TIA	<u> </u>	
and	naximum of 21 days following minor stroke or TIA		

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2530 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Ticagrelor - continued		
Renewal — subsequent minor stroke or TIA, or	Crescendo TIA	
Current approval Number (if known):		
Applications from any relevant practitioner. Approx Prerequisites (tick box where appropriate)	vals valid for 1 month.	
Patient has been diagnosed with a minor Crescendo TIA	stroke (NIHSS score 3 or less) or high-risk transien	t ischemic attack (ABCD2 score 4 or more) or

Note: indications marked with * are unapproved indications.

Note: Note:** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Note: Note:NIHSS† National Institutes of Health Stroke Scale.

I confirm the above details are correct and that in signing this form I understand I may be audited.